Literature DB >> 19273909

Ca2+/calmodulin-dependent kinase II triggers cell membrane injury by inducing complement factor B gene expression in the mouse heart.

Madhu V Singh1, Ann Kapoun, Linda Higgins, William Kutschke, Joshua M Thurman, Rong Zhang, Minati Singh, Jinying Yang, Xiaoqun Guan, John S Lowe, Robert M Weiss, Kathy Zimmermann, Fiona E Yull, Timothy S Blackwell, Peter J Mohler, Mark E Anderson.   

Abstract

Myocardial Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibition improves cardiac function following myocardial infarction (MI), but the CaMKII-dependent pathways that participate in myocardial stress responses are incompletely understood. To address this issue, we sought to determine the transcriptional consequences of myocardial CaMKII inhibition after MI. We performed gene expression profiling in mouse hearts with cardiomyocyte-delimited transgenic expression of either a CaMKII inhibitory peptide (AC3-I) or a scrambled control peptide (AC3-C) following MI. Of the 8,600 mRNAs examined, 156 were substantially modulated by MI, and nearly half of these showed markedly altered responses to MI with CaMKII inhibition. CaMKII inhibition substantially reduced the MI-triggered upregulation of a constellation of proinflammatory genes. We studied 1 of these proinflammatory genes, complement factor B (Cfb), in detail, because complement proteins secreted by cells other than cardiomyocytes can induce sarcolemmal injury during MI. CFB protein expression in cardiomyocytes was triggered by CaMKII activation of the NF-kappaB pathway during both MI and exposure to bacterial endotoxin. CaMKII inhibition suppressed NF-kappaB activity in vitro and in vivo and reduced Cfb expression and sarcolemmal injury. The Cfb-/- mice were partially protected from the adverse consequences of MI. Our findings demonstrate what we believe is a novel target for CaMKII in myocardial injury and suggest that CaMKII is broadly important for the genetic effects of MI in cardiomyocytes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273909      PMCID: PMC2662543          DOI: 10.1172/JCI35814

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  64 in total

1.  Ca2+-dependent protein phosphorylation system in membranes from various tissues, and its activation by "calcium-dependent regulator".

Authors:  H Schulman; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

2.  Sublytic complement attack protects tumor cells from lytic doses of antibody and complement.

Authors:  Y Reiter; A Ciobotariu; Z Fishelson
Journal:  Eur J Immunol       Date:  1992-05       Impact factor: 5.532

Review 3.  Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link?

Authors:  P Vallance; J Collier; K Bhagat
Journal:  Lancet       Date:  1997-05-10       Impact factor: 79.321

4.  Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation.

Authors:  K S Kilgore; E Schmid; T P Shanley; C M Flory; V Maheswari; N L Tramontini; H Cohen; P A Ward; H P Friedl; J S Warren
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

5.  Effects of complement activation in the isolated heart. Role of the terminal complement components.

Authors:  J W Homeister; P Satoh; B R Lucchesi
Journal:  Circ Res       Date:  1992-08       Impact factor: 17.367

6.  Isolation and characterization of the mouse cardiac myosin heavy chain genes.

Authors:  J Gulick; A Subramaniam; J Neumann; J Robbins
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

7.  Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels.

Authors:  Stefan Wagner; Nataliya Dybkova; Eva C L Rasenack; Claudius Jacobshagen; Larissa Fabritz; Paulus Kirchhof; Sebastian K G Maier; Tong Zhang; Gerd Hasenfuss; Joan Heller Brown; Donald M Bers; Lars S Maier
Journal:  J Clin Invest       Date:  2006-11-22       Impact factor: 14.808

8.  Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle. A possible initiator of an extra myocardial mechanism of ischemic injury.

Authors:  R D Rossen; J L Swain; L H Michael; S Weakley; E Giannini; M L Entman
Journal:  Circ Res       Date:  1985-07       Impact factor: 17.367

Review 9.  Inflammation in the course of early myocardial ischemia.

Authors:  M L Entman; L Michael; R D Rossen; W J Dreyer; D C Anderson; A A Taylor; C W Smith
Journal:  FASEB J       Date:  1991-08       Impact factor: 5.191

Review 10.  Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease.

Authors:  M L Entman; C W Smith
Journal:  Cardiovasc Res       Date:  1994-09       Impact factor: 10.787

View more
  71 in total

Review 1.  CaMKII in myocardial hypertrophy and heart failure.

Authors:  Mark E Anderson; Joan Heller Brown; Donald M Bers
Journal:  J Mol Cell Cardiol       Date:  2011-01-27       Impact factor: 5.000

Review 2.  Is CaMKII a link between inflammation and hypertrophy in heart?

Authors:  Madhu V Singh; Mark E Anderson
Journal:  J Mol Med (Berl)       Date:  2011-01-29       Impact factor: 4.599

3.  Pivotal advance: The pattern recognition receptor ligands lipopolysaccharide and polyinosine-polycytidylic acid stimulate factor B synthesis by the macrophage through distinct but overlapping mechanisms.

Authors:  David J Kaczorowski; Amin Afrazi; Melanie J Scott; Joon H Kwak; Roop Gill; Rebecca D Edmonds; Yujian Liu; Jie Fan; Timothy R Billiar
Journal:  J Leukoc Biol       Date:  2010-04-22       Impact factor: 4.962

4.  CaMKII is essential for the proasthmatic effects of oxidation.

Authors:  Philip N Sanders; Olha M Koval; Omar A Jaffer; Anand M Prasad; Thomas R Businga; Jason A Scott; Patrick J Hayden; Elizabeth D Luczak; David D Dickey; Chantal Allamargot; Alicia K Olivier; David K Meyerholz; Alfred J Robison; Danny G Winder; Timothy S Blackwell; Ryszard Dworski; David Sammut; Brett A Wagner; Garry R Buettner; Robert M Pope; Francis J Miller; Megan E Dibbern; Hans Michael Haitchi; Peter J Mohler; Peter H Howarth; Joseph Zabner; Joel N Kline; Isabella M Grumbach; Mark E Anderson
Journal:  Sci Transl Med       Date:  2013-07-24       Impact factor: 17.956

5.  The sepsis seesaw: seeking a heart salve.

Authors:  Peter A Ward
Journal:  Nat Med       Date:  2009-05       Impact factor: 53.440

6.  Mitochondrial CaMKII inhibition in airway epithelium protects against allergic asthma.

Authors:  Sara C Sebag; Olha M Koval; John D Paschke; Christopher J Winters; Omar A Jaffer; Ryszard Dworski; Fayyaz S Sutterwala; Mark E Anderson; Isabella M Grumbach
Journal:  JCI Insight       Date:  2017-02-09

7.  Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca2+/Calmodulin-Dependent Protein Kinase II δ Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling.

Authors:  Takeshi Suetomi; Andrew Willeford; Cameron S Brand; Yoshitake Cho; Robert S Ross; Shigeki Miyamoto; Joan Heller Brown
Journal:  Circulation       Date:  2018-11-27       Impact factor: 29.690

8.  The multifunctional Ca2+/calmodulin-dependent kinase II regulates vascular smooth muscle migration through matrix metalloproteinase 9.

Authors:  Jason A Scott; Litao Xie; Hui Li; Weiwei Li; Julie B He; Philip N Sanders; A Brent Carter; Johannes Backs; Mark E Anderson; Isabella M Grumbach
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-16       Impact factor: 4.733

9.  Ca2+/Calmodulin-dependent protein kinase II δ mediates myocardial ischemia/reperfusion injury through nuclear factor-κB.

Authors:  Haiyun Ling; Charles B B Gray; Alexander C Zambon; Michael Grimm; Yusu Gu; Nancy Dalton; Nicole H Purcell; Kirk Peterson; Joan Heller Brown
Journal:  Circ Res       Date:  2013-02-06       Impact factor: 17.367

Review 10.  New therapeutic targets in cardiology: arrhythmias and Ca2+/calmodulin-dependent kinase II (CaMKII).

Authors:  Adam G Rokita; Mark E Anderson
Journal:  Circulation       Date:  2012-10-23       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.